Andere Sprachen Genome & Company

Aktien

A314130

KR7314130006

A314130

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 10.05.2024			% 5 Tage	% 1. Jan.
7 180 ^KRW	0,00 %		+4,82 %	-42,51 %

24.01.	Genome & Company gibt positive Topline-Ergebnisse der klinischen Phase-2-Studie mit der Kombination von GEN-001 und Bavencio®? zur Behandlung von Magenkrebs bekannt Poster auf der ASCO GI vorgestellt	CI
2023	Genome & Company gibt positive Ergebnisse der Zwischenanalyse der Phase II-Studie mit Gen-001 plus Avelumab (Bavencio®?) bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24.01.
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19.05.23
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07.04.23
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05.04.23
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02.09.22
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18.08.22
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04.03.22
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21.09.21
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20.09.21
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08.09.21
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09.03.21
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25.02.21
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27.10.20
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26.08.20
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11.08.20
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07.08.20
Genome & Company announced that it has received KRW 4.00002 billion in funding	25.06.20
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17.06.20
Genome & Company announced that it has received KRW 3.62991 billion in funding	24.04.20
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20.04.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Genome & Company

Aktien

A314130

KR7314130006

A314130

Andere Sprachen

Filter